US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, reported on Thursday that the Phase 3 KEYLYNK-006 trial, evaluating KEYTRUDA (pembrolizumab) in combination with maintenance LYNPARZA (olaparib), did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).

The trial compared KEYTRUDA with chemotherapy followed by KEYTRUDA plus maintenance LYNPARZA to KEYTRUDA with chemotherapy followed by KEYTRUDA plus maintenance chemotherapy. The safety profiles of both drugs remained consistent with previous studies.

Merck said that it continues to evaluate the trial data and plans to share results with the scientific community in collaboration with investigators.